BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19803555)

  • 1. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans.
    Ramsey SD; Scoggins JF; Blough DK; McDermott CL; Reyes CM
    J Manag Care Pharm; 2009 Oct; 15(8):659-68. PubMed ID: 19803555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
    Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
    Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
    Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
    Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer.
    Onukwugha E; Yong C; Hussain A; Seal B; Mullins CD
    BMC Med Res Methodol; 2014 Jan; 14():1. PubMed ID: 24383436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of administrative claims data for the study of brain metastases: a validation study.
    Eichler AF; Lamont EB
    J Neurooncol; 2009 Dec; 95(3):427-431. PubMed ID: 19562256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administrative and claims records as sources of health care cost data.
    Riley GF
    Med Care; 2009 Jul; 47(7 Suppl 1):S51-5. PubMed ID: 19536019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data.
    Ammann EM; Kalsekar I; Yoo A; Johnston SS
    Pharmacoepidemiol Drug Saf; 2018 Oct; 27(10):1092-1100. PubMed ID: 30003617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.
    Baumgardner J; Shahabi A; Linthicum M; Vine S; Zacker C; Lakdawalla D
    J Manag Care Spec Pharm; 2018 Jun; 24(6):504-513. PubMed ID: 29799330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
    Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
    Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in US Ambulatory Care Patterns During the COVID-19 Pandemic, 2019-2021.
    Mafi JN; Craff M; Vangala S; Pu T; Skinner D; Tabatabai-Yazdi C; Nelson A; Reid R; Agniel D; Tseng CH; Sarkisian C; Damberg CL; Kahn KL
    JAMA; 2022 Jan; 327(3):237-247. PubMed ID: 35040886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
    Gold HT; Do HT
    Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of coding algorithms to identify patients with incident lung cancer in United States healthcare claims data.
    Beyrer J; Nelson DR; Sheffield KM; Huang YJ; Ellington T; Hincapie AL
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1465-1479. PubMed ID: 33012044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data.
    Feliciano J; Gardner L; Hendrick F; Edelman MJ; Davidoff A
    Lung Cancer; 2015 Jan; 87(1):59-64. PubMed ID: 25443272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Medicare Beneficiaries Accessing Transgender-Related Care in the Era of ICD-10.
    Ewald ER; Guerino P; Dragon C; Laffan AM; Goldstein Z; Streed C
    LGBT Health; 2019; 6(4):166-173. PubMed ID: 31084519
    [No Abstract]   [Full Text] [Related]  

  • 18. Race and sex differences in the receipt of timely and appropriate lung cancer treatment.
    Shugarman LR; Mack K; Sorbero ME; Tian H; Jain AK; Ashwood JS; Asch SM
    Med Care; 2009 Jul; 47(7):774-81. PubMed ID: 19536007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construct validity of medicare chemotherapy claims: the case of 5FU.
    Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
    Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using administrative data to study persons with disabilities.
    Iezzoni LI
    Milbank Q; 2002; 80(2):347-79. PubMed ID: 12101876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.